GANX — Gain Therapeutics Balance Sheet
0.000.00%
- $159.23m
- $150.85m
Annual balance sheet for Gain Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7.49 | 36.9 | 20.1 | 16.8 | 10.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.067 | 0.195 | 0.191 | 0.243 | 0.766 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 8.99 | 37.7 | 21.1 | 17.8 | 11.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.553 | 1.21 | 1.02 | 0.779 | 0.323 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 9.6 | 39 | 24.1 | 18.6 | 12.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.11 | 2.55 | 4.13 | 4.95 | 3.91 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3.4 | 4.17 | 5.22 | 6.03 | 4.78 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 6.2 | 34.8 | 18.9 | 12.6 | 7.34 |
| Total Liabilities & Shareholders' Equity | 9.6 | 39 | 24.1 | 18.6 | 12.1 |
| Total Common Shares Outstanding |